| Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts. | |
| | |
MedLine Citation:
|
PMID: 12047036 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We investigated the effects of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, pravastatin, an angiotensin converting enzyme (ACE) inhibitor, temocaprilat, and an angiotensin II type 1 (AT1) receptor antagonist, CV-11974, on myocardial metabolism during ischemia in isolated rabbit hearts using phosphorus 31-nuclear magnetic resonance (31P-NMR) imaging. Forty-five minutes of continuous normothermic global ischemia was carried out. Pravastatin, temocaprilat, CV-11974 or a nitric oxide synthase inhibitor, L-NAME was administered from 60 min prior to the global ischemia. Japanese white rabbits were divided into the following experimental groups, a control group (n=7), a group treated with pravastatin (P group; n=7), a group treated with pravastatin and temocaprilat (P+T group; n=7), a group treated with pravastatin and CV-11974 (P+CV group; n=7), and a group treated with pravastatin and L-NAME (P+L-NAME group; n=7). During ischemia, P group, as well as either P+T group or P+CV group, showed a significant inhibition of the decreases in adenosine triphosphate (ATP) and intracellular pH (pHi) (p<0.01, respectively, at the end of ischemia compared to the control group as well as P+L-NAME group), and a significant inhibition of the increase in inorganic phosphate (Pi) (p<0.01, respectively, compared with the control group as well as P+L-NAME group). These results suggest that pravastatin significantly improved myocardial energy metabolism during myocardial ischemia. This beneficial effect was dependent on NO synthase. However, this beneficial effect was not enhanced by either temocaprilat or CV-11974. |
| | |
Authors:
|
Hitoshi Kawabata; Kizuku Nakagawa; Kinji Ishikawa |
Related Documents
:
|
9420696 - Investigation of myocardial metabolism for the study of the pathophysiology of cardiac ... 1986156 - Studies of myocardial protection in the immature heart. iii. models of ischemic and hyp... 23273746 - Ecg-based signal analysis technologies for evaluating patients with acute coronary synd... 10340236 - Symptomatic myocardial ischemia and everyday life: implications for clinical use of int... 6778166 - Percutaneous transluminal angioplasty: general principles. 7471316 - Early detection of doxorubicin cardiotoxicity by m-mode echocardiography. |
Publication Detail:
|
Type: In Vitro; Journal Article |
Journal Detail:
|
Title: Hypertension research : official journal of the Japanese Society of Hypertension Volume: 25 ISSN: 0916-9636 ISO Abbreviation: Hypertens. Res. Publication Date: 2002 Mar |
Date Detail:
|
Created Date: 2002-06-05 Completed Date: 2002-11-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9307690 Medline TA: Hypertens Res Country: Japan |
Other Details:
|
Languages: eng Pagination: 203-10 Citation Subset: IM |
Affiliation:
|
First Department of Internal Medicine, Kinki University School of Medicine, Osakasayama, Japan. int1@med.kindai.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenosine Triphosphate
/
metabolism Angiotensin-Converting Enzyme Inhibitors / pharmacology* Animals Antihypertensive Agents / pharmacology Benzimidazoles / pharmacology Cardiotonic Agents / pharmacology Drug Combinations Enzyme Inhibitors / pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology* Myocardial Ischemia / metabolism* Myocardium / metabolism* NG-Nitroarginine Methyl Ester / pharmacology Phosphates / metabolism Pravastatin / pharmacology Rabbits Receptor, Angiotensin, Type 1 Receptors, Angiotensin / antagonists & inhibitors* Tetrazoles / pharmacology Thiazepines / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Cardiotonic Agents; 0/Drug Combinations; 0/Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Phosphates; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Angiotensin; 0/Tetrazoles; 0/Thiazepines; 110221-53-9/temocaprilat; 139481-59-7/candesartan; 50903-99-6/NG-Nitroarginine Methyl Ester; 56-65-5/Adenosine Triphosphate; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed ra...
Next Document: Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expres...